A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumors

PURPOSE: This phase I study was carried out to determine the phase II recommended dose of tasisulam sodium (hereafter, tasisulam), a novel anticancer agent with a unique mechanism of action. METHODS: Tasisulam was administered intravenously, every 21 days, in patients with refractory solid tumors us...

Descripción completa

Detalles Bibliográficos
Autores principales: Simon, George R., Ilaria, Robert L., Sovak, Mika A., Williams, Charles C., Haura, Eric B., Cleverly, Ann L., Sykes, Amanda K., Wagner, Margaret M., de Alwis, Dinesh P., Slapak, Christopher A., Miller, Mary A., Spriggs, David R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2011
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3215883/
https://www.ncbi.nlm.nih.gov/pubmed/21431416
http://dx.doi.org/10.1007/s00280-011-1593-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3215883/
https://www.ncbi.nlm.nih.gov/pubmed/21431416
http://dx.doi.org/10.1007/s00280-011-1593-0

Ejemplares similares